Selective CCR2 antagonists

1. A compound according to formula (I),

wherein R 3 is a group selected from among

wherein R 14 is a group selected from among —H, —C 1 -C 6 -alkyl, —CN, —CF 3 , —OCF 3 , halogen, and —C(O)—CH 3 ;

wherein R 15 is a group selected from among —H, —C 1 -C 6 -alkyl, —CN, —CF 3 , and —C(O)—CH 3 ; and

wherein R 16 is a group selected from among —H, —C 1 -C 6 -alkyl, —CN, —CF 3 , —OCF 3 , halogen, and —C(O)—CH 3 ;

or wherein R 3 denotes a group selected from among —CH 2 F, —CHF 2 , and —CF 3 ;

wherein A is a group selected from among

wherein R 7 is selected from among —H, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 , and wherein R 8 is selected from among —H, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 ,

wherein Q is selected from among CH 2 and O, and wherein R 9 is selected from among —H, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 , and wherein R 10 is selected from among —H, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 ;

R 6 is a group of the structure -L 1 —R 13 ,

wherein L 1 is selected from among —NH—, and —N(C 1 -C 4 -alkyl)- ,

and wherein R 13 is selected from among —C 5 -C 6 -heterocyclyl comprising 1 or 2 hetero atoms selected from among N, and O,

and wherein R 13 is optionally substituted by one or more groups selected from among among —CF 3 , —OCF 3 , —CN, —OH, —O—C 1 -C 4 -alkyl, —C 1 -C 6 -alkyl, and -halogen;

or R 6 is a group of the structure —N(R 1 ,R 1 ′),

wherein R 1 and R 1 , , together form a —C 2 -C 6 -alkylene group such that a ring is formed, wherein one carbon atom may be replaced by a group selected from among NH, and O,

and wherein such ring is optionally substituted with one or more groups selected from among —OH, —OCH 3 , —CF 3 , —OCF 3 , —CN, -halogen, —C 1 -C 4 -alkyl, ═O, and —N(C 0 -C 3 -alkyl)-SO 2 —C 1 -C 3 -alkyl;

R 2 is selected from among —H, -halogen, —CN, —O—C 1 -C 4 -alkyl, —C 1 -C 1 -alkyl, —CH═CH 2 , —C≡CH, -cyclopropyl, —CF 3 , —OCF 3 , —OCF 2 H, and —OCFH 2 ;

R 4 is selected from among —H, —C 1 -C 4 -alkyl, —OH, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 ;

R 5 is selected from among —H, —C 1 -C 1 -alkyl, —OH, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 ;

G and E are N; and

n is 1, 2 or 3;

or an acid addition salt with a pharmacologically acceptable acid.

2. The compound of claim 1 ,

wherein R 3 is a group selected from among

wherein R 14 is a group selected from among —H, —C 1 -C 6 -alkyl, —CN, —CF 3 , —OCF 3 , halogen, and —C(O)—CH 3 ;

wherein R 15 is a group selected from among —H, —C 1 -C 6 -alkyl, —CN, —CF 3 , and —C(O)—CH 3 ; and

wherein R 16 is a group selected from among —H, —C 1 -C 6 -alkyl, —CN, —CF 3 , —OCF 3 , halogen, and —C(O)—CH 3 .

3. The compound of claim 1 ,

wherein R 3 is a group selected from among —CH 2 F, —CHF 2 , and —CF 3 .

4. The compound of claim 1 ,wherein A is a group of the structure

wherein Q denotes CH 2 , and wherein R 9 denotes —H, and wherein R 10 is a group selected from among —H, —CH 3 , and —CF 3 .

5. The compound of claim 1 , wherein A is a group of the structure

wherein R 7 is selected from among —H, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 ; and

wherein R 8 is selected from among —H, —C 1 -C 1 -alkyl, —O—C 1 -C 4 -alkyl, -halogen, —CN, —CF 3 , and —OCF 3 .

6. The compound of claim 1 , wherein R 2 is a group selected from among —H, —CH 3 , —OCH 3 , and -cyclopropyl.

7. The compound of claim 1 , wherein R 4 is selected from among —H, —CH 3 , —OCH 3 , —CF 3 , and —OH.

8. The compound of claim 1 , wherein R 5 is selected from among —H, —CH 3 , —C 2 H 5 , —O—CH 3 , —O—C 2 H 5 , —F, —CF 3 , and —OCF 3 .

9. The compound of claim 1 , wherein R 6 is a group of the structure -L 1 -R 13 ,

wherein L 1 is selected from among —NH—, and —N(CH 3 )—,

wherein R 13 is —C 6 -heterocyclyl comprising an O atom, and

wherein R 13 is optionally substituted by a group selected from among —O—C 1 -C 4 -alkyl, and -halogen.

10. The compound of claim 1 , wherein R 6 is a group of the structure-N (R 1 ,R 1 ′),

wherein R 1 and R 1′ , together form a —C 5 -alkylene group such that a ring is formed,

wherein one carbon atom may be replaced by a group selected from among O,

and wherein such ring is optionally substituted with one or more groups selected from among —OH, —OCH 3 —CF 3 , —OCF 3 —CN, -halogen, —C 1 -C 1 -alkyl, ═O, and —N(C 0 -C 1 -alkyl)—SO 2 —C 1 -C 3 -alkyl.

11. The compound of claim 1 , wherein n is 2.

12. A compound according to claim 1 , selected from the group consisting of

or an acid addition salt with a pharmacologically acceptable acid.

13. A compound selected from the group consisting of

or an acid addition salt with a pharmacologically acceptable acid.